U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT04846998) titled 'A Study to Compare the Pharmacokinetics of BR9003A and BR9003 in Healthy Adult Subjects' on April 14.
Brief Summary: The purpose of this study is to evaluate the pharmacokinetics and safety of oral administration of BR9003 compared with BR9003A in healthy adult subjects
Study Type: Interventional
Condition: Smoking Cessation
Intervention: * Drug: BR9003
Treatment group B:
Once-daily oral administration of one BR9003 2mg tablet in the fasting state.
Treatment group C:
Once-daily oral administration of one BR9003 2mg tablet after a meal(high-fat meal) 30 minutes before the scheduled time of administration and finishing it.
* ...